Results 141 to 150 of about 17,592 (206)

Real-World Outcomes of Palbociclib with Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer: A Retrospective Study from Saudi Arabia. [PDF]

Cancers (Basel)
Alanizi AH, Al-Shaiban SN, Alotaibi R, Qubaiban R, Khader E, Alanazi AS, Bakhribah H, Alsubaie N, Alrossies AS, Shilbayeh SAR, Binsaleh AY.   +10 more
europepmc   +1 more source

Body Mass Index and Outcomes in HR+/HER2- Metastatic Breast Cancer Treated with Palbociclib: Insights from a National Real-World Study. [PDF]

Cancers (Basel)
Badau LM, Epure P, Margan MM, Margan R, Ciocoiu AD, Oprean CM, Vlaicu B.   +6 more
europepmc   +1 more source

Comparative effectiveness of CDK4/6 inhibitor plus endocrine therapy combinations in HR-positive, HER2-negative metastatic breast cancer: the inspiration 01 study. [PDF]

Front Pharmacol
Jia Y, Zhang J, Wang X, Hao C, Wang C, Li S, Lu N, Dong G, Zhao W, Jia Y, Huang L, Gu J, Shi Y, Tong Z.   +13 more
europepmc   +1 more source

Combined CDK4/6 Inhibition and Radiation: Effects on Cellular Senescence, Cell Cycle Regulation, and Cell Death in Mammary Carcinoma Cells. [PDF]

Cells
Quarz L, Distel LV, Corradini S, Hildebrand LS.   +3 more
europepmc   +1 more source

Comparative real-world progression free survival of CDK4/6 inhibitors in HR+/HER2- breast cancer patients with bone metastases. [PDF]

Oncologist
Scafetta R, Donato M, Gullotta C, Guarino A, Fiore C, Sisca L, Speziale E, Troiano R, Foderaro S, Venuti F, Vilardi FA, Ricozzi V, Iuliani M, Simonetti S, Cavaliere S, Cortellini A, La Cesa A, Botticelli A, Scagnoli S, Pisegna S, Criscitiello C, Chirco A, D'Alessandro S, Pedersini R, Sposetti C, Tiberi E, D'Auria G, Vergati M, Mazzotta M, Caputo R, Verrazzo A, Rossino MG, Domati F, Piombino C, Di Lisa FS, Filomeno L, Arcuri T, Puce F, Riva F, Palleschi M, Sirico M, Piras M, Stucci LS, De Lisi D, Orsaria P, Grasso A, Ippolito E, Ramella S, Visani L, Bertini N, Bonaparte I, Gori S, Rossi L, Meattini I, Tagliaferri B, Caffo O, Bonomo MV, Portarena I, Irelli A, Cretella E, Porta C, Bianchini G, Fabbri MA, De Giorgi U, Vici P, Toss A, Garrone O, De Laurentiis M, Villa F, Berardi R, Minelli M, Altomare V, Vernieri C, Curigliano G, Vincenzi B, Tonini G, Santini D, Pantano F.   +77 more
europepmc   +1 more source

Cell size modulates ferroptosis susceptibility. [PDF]

Elife
Zatulovskiy E, Murray MB, Zhang S, Dixon SJ, Skotheim JM.   +4 more
europepmc   +1 more source

Real-world progression-free survival 2 (PFS2) and tumor response of CDK4/6 inhibitors plus an aromatase inhibitor in patients with HR+/HER2- metastatic breast cancer in US routine clinical practice. [PDF]

Breast
Rugo HS, Brufsky A, Layman RM, Liu X, Li B, McRoy L, Cohen AB, Estevez M, Lynce F, Cottu P, Thill M, Curigliano G.   +11 more
europepmc   +1 more source

Impact of Comorbidities on Clinical Outcomes and Quality of Life of Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer Treated With Palbociclib in the POLARIS Study. [PDF]

Cancer Med
Tripathy D, Blum JL, Karuturi MS, McCune S, Kurian S, Moezi MM, Anderson DM, Ji Y, Pluard TJ, Migas J, Lakhanpal S, Jepsen E, Wang Y, Montelongo MZ, Zhang Z, Cappelleri JC, Gauthier E, Rocque GB.   +17 more
europepmc   +1 more source

A Rare Case of Palbociclib-Induced Pancolitis: Clinical Insights and Literature Review. [PDF]

Cureus
Bidani K, Chouthai AA, Broder A, Velpari S.   +3 more
europepmc   +1 more source

"Carry-Over" Effect of CDK4/6 Inhibitors in Adjuvant Therapy for Hormone Receptor (HR)-Positive/HER2-Negative Early Breast Cancer: Clinical Evidence and Molecular Approach. [PDF]

Biomedicines
Valencia G, Morante Z, Ferreyra Y, Jacome R, Rioja P, Saavedra A, Neciosup S, Vidaurre T, Gómez HL.   +8 more
europepmc   +1 more source